- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04553133
PF-07104091 as a Single Agent and in Combination Therapy
March 8, 2023 updated by: Pfizer
PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
- Drug: PF-07104091 monotherapy dose escalation
- Drug: PF-07104091 + palbociclib + fulvestrant
- Drug: PF-07104091 + palbociclib + letrozole
- Drug: PF-07104091 monotherapy dose expansion (SCLC)
- Drug: PF-07104091 monotherapy dose expansion (ovarian)
- Drug: PF-0704091 + Fulvestrant (post CDK4/6)
- Drug: PF-07104091 + Fulvestrant (post CDK4/6)
Detailed Description
Study C4161001 is a Phase 1, open label, multi dose, multi center, dose escalation, safety, pharmacokinetic (PK) and pharmacodynamic study of PF-07104091 in adult patients with advanced or metastatic small cell lung cancer (SCLC), advanced platinum resistant epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer, locally recurrent/advanced or metastatic triple negative breast cancer (TNBC), HR-positive HER2-negative advanced or mBC, advanced or metastatic non-small cell lung cancer (NSCLC).
This two part study will assess the safety and tolerability of increasing dose levels of PF-07104091 in Part 1, and establish the recommended Phase 2 dose (RP2D) in Part 2.
Study Type
Interventional
Enrollment (Anticipated)
320
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Not yet recruiting
- Tianjin Medical University Cancer Institute & Hospital
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Recruiting
- National Cancer Center Hospital East
-
-
Tokyo
-
Koto, Tokyo, Japan, 135-8550
- Recruiting
- The Cancer Institute Hospital of JFCR
-
-
-
-
-
Oaxaca, Mexico, 68000
- Not yet recruiting
- Oaxaca Site Management Organization
-
-
Distrito Federal
-
Mexico City, Distrito Federal, Mexico, 04700
- Not yet recruiting
- COI Centro Oncologico Internacional S.A.P.I. de C.V.
-
-
Nuevo LEÓN
-
Monterrey, Nuevo LEÓN, Mexico, 64460
- Not yet recruiting
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
-
-
-
-
Iowa
-
Clive, Iowa, United States, 50325
- Recruiting
- Medical Oncology & Hematology Associates DBA Mission Cancer and Blood
-
Des Moines, Iowa, United States, 50309
- Recruiting
- Des Moines Oncology Research Association
-
Des Moines, Iowa, United States, 50309
- Recruiting
- Medical Oncology & Hematology Associates DBA Mission Cancer and Blood
-
Des Moines, Iowa, United States, 50314
- Recruiting
- Medical Oncology & Hematology Associates DBA Mission Cancer and Blood
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Cancer Institute, Downtown
-
Louisville, Kentucky, United States, 40241
- Recruiting
- Norton Brownsboro Hospital
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Hospital
-
Louisville, Kentucky, United States, 40207
- Recruiting
- Norton Cancer Institute, St. Matthews
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Cancer Institute Downtown
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Cancer Institute Pharmacy, Downtown Pharmacy
-
Louisville, Kentucky, United States, 40207
- Recruiting
- Norton Women's and Children's Hospital (St. Matthews)
-
Louisville, Kentucky, United States, 40217
- Recruiting
- Norton Cancer Institute, Audubon
-
Louisville, Kentucky, United States, 40217
- Recruiting
- Norton Hospital (Audubon)
-
Louisville, Kentucky, United States, 40241
- Recruiting
- Norton Cancer Institute, Brownsboro Campus
-
Louisville, Kentucky, United States, 40291
- Recruiting
- Norton Diagnostic Center - Fern Creek
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana Farber Cancer Institute
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham & Women's Hospital
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- Recruiting
- START Midwest
-
-
New Jersey
-
Middletown, New Jersey, United States, 07748
- Recruiting
- Memorial Sloan Kettering Monmouth
-
-
New York
-
Harrison, New York, United States, 10604
- Recruiting
- Memorial Sloan Kettering Westchester
-
Mineola, New York, United States, 11501
- Recruiting
- NYU Langone Hospital - Long Island
-
Mineola, New York, United States, 11501
- Recruiting
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10016
- Recruiting
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone Medical Center (Tisch Hospital)
-
New York, New York, United States, 10016
- Recruiting
- Laura & Isaac Perlmutter Cancer Center - NYU ACC
-
New York, New York, United States, 10022
- Recruiting
- MSK Rockefeller Outpatient Pavilion
-
White Plains, New York, United States, 10601
- Not yet recruiting
- White Plains Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas MD Anderson Cancer Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Not yet recruiting
- University of Virginia Health System
-
Charlottesville, Virginia, United States, 22903
- Not yet recruiting
- University of Virginia Cancer Center
-
Charlottesville, Virginia, United States, 22911
- Not yet recruiting
- UVA Breast Care Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants with HR-positive HER2-negative advanced or metastatic breast cancer (received at least two prior lines in the advanced or metastatic setting including one prior line of combined CDK4/6 inhibitor and endocrine therapy and no more than two prior lines of cytotoxic chemotherapy)
- Participants with locally recurrent/advanced or metastatic TNBC who have received up to 2 prior lines of chemotherapy in the advanced or metastatic setting
- Participants with advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC) (histologically or cytologically proven) who have received at least 1 systemic anti-cancer therapy containing a platinum analog
- Participants with cytological diagnosis of advanced/metastatic SCLC
- Participants with or cytological diagnosis of advanced/metastatic NSCLC
- Participants with HR-positive HER2-negative advanced or metastatic breast cancer (second line plus setting) (histologically or cytologically proven).
- Participants entering the study in the expansion cohort have at least one measurable lesion as defined by RECIST version 1.1 that has not been previously irradiated
- Performance Status 0 or 1
- Adequate bone marrow, hematological, kidney and liver function
- Resolved acute effects of any prior therapy to baseline severity
Exclusion Criteria:
- Participants with known symptomatic brain metastases requiring steroids
- Participants with any other active malignancy within 3 years prior to enrollment
- Major surgery within 3 weeks prior to study entry
- Radiation therapy within 3 weeks prior to study entry.
- Systemic anti cancer therapy within 4 weeks prior to study
- Prior irradiation to >25% of the bone marrow
- Participants with active, uncontrolled bacterial, fungal, or viral infection, including HBV, HCV, and known HIV or AIDS related illness
- Active COVID-19/SARS-CoV2 infection
- Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
- Any of the following in the previous 6 months: myocardial infarction, long QT syndrome, Torsade de Pointes, arrhythmias, serious conduction system abnormalities, unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF, New York Heart Association class III or IV, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, and/or other clinical significant episode of thrombo embolic disease.
- Anticoagulation with vitamin K antagonists or factor Xa inhibitors is not allowed.
- Hypertension that cannot be controlled by medications
- Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry.
- Known or suspected hypersensitivity to active ingredient/excipients in PF 07104091.
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Participants with advanced/metastatic, symptomatic, visceral spread, that are at risk of life threatening complications in the short
- Participants with an indwelling catheter that has an external component such as those used for drainage of effusion(s) or central venous catheter that is externally
- Previous high dose chemotherapy requiring stem cell rescue
- Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of goserelin (if applicable).
- Current use or anticipated need for food or drugs that are known strong CYP3A4/5 or UGT1A9 inhibitors or inducers
- Current use or anticipated need for drugs that are known sensitive UGT1A1 substrates with narrow therapeutic
- Serum pregnancy test positive at screening
- Other medical or psychiatric condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PF-07104091
CDK2 monotherapy dose escalation
|
PF-07104091 will be administered orally
|
Experimental: PF-07104091 + palbociclib + fulvestrant
CDK2 + palbociclib + fulvestrant
|
PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
|
Experimental: PF-07104091 + palbociclib + letrozole
CDK2 + palbociclib + letrozole
|
PF-07104091 will be administered orally in combination with palbociclib and letrozole
|
Experimental: PF-07104091 monotherapy dose expansion (SCLC)
|
PF-07104091 will be administered orally
|
Experimental: PF-07104091 monotherapy dose expansion (ovarian)
|
PF-07104091 will be administered orally
|
Experimental: PF-07104091 + fulvestrant (post CDK4/6) dose expansion
|
PF-07104091 + fulvestrant (post 4/6) dose expansion
|
Experimental: PF-07104091 + fulvestrant (post CDK 4/6) dose escalation
CDK2+ fulvestrant (post CDK 4/6) dose escalation
|
PF-07104091 will be administered orally in combination with fulvestrant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle
Time Frame: 28 days
|
Number of participants with DLTs, which are typically Grade 3 or higher adverse events will be summarized by dose level
|
28 days
|
To evaluate incidence of treatment emergent adverse events and laboratory abnormalities
Time Frame: From baseline until end of study treatment or study completion (approximately 2 years)
|
Type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and any laboratory abnormalities will be summarized by dose level
|
From baseline until end of study treatment or study completion (approximately 2 years)
|
Evaluate pulse rate that is out of normal range and changes in pulse rate as compared to baseline
Time Frame: From baseline until end of study treatment or study completion (approximately 2 years)
|
Identify pulse rate readings that are outside the normal range.
The number and percentage of participants who experienced significant pulse rate change from baseline will be summarized by dose level
|
From baseline until end of study treatment or study completion (approximately 2 years)
|
Evaluate blood pressure that is out of normal range and changes in blood pressure as compared to baseline
Time Frame: From baseline until end of study treatment or study completion (approximately 2 years)
|
Identify systolic and diastolic readings that are outside the normal range.
The number and percentage of participants who experienced significant blood pressure change from baseline will be summarized by dose level
|
From baseline until end of study treatment or study completion (approximately 2 years)
|
To evaluate heart rate corrected QT interval and changes in corrected QT interval as compared to baseline
Time Frame: From baseline until end of study treatment or study completion (approximately 2 years)
|
Determine the effect of the drug on QT prolongation.
The number and percentage of participants who experienced QT interval prolongation will be summarized by dose level
|
From baseline until end of study treatment or study completion (approximately 2 years)
|
To evaluate the preliminary antitumor activity of PF-07104091 as a single agent and in combination with palbociclib and in combination with letrozole or fulvestrant or fulvestrant alone by objective response rate (ORR) in dose expansion
Time Frame: From baseline through disease progression or study completion (approximately 2 years)
|
Percentage of participants with a best overall response of complete response (CR) or partial response (PR) using RECIST 1.1
|
From baseline through disease progression or study completion (approximately 2 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax) of PF-07104091 after a single dose and multiple dose
Time Frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Peak concentration of PF-07104091 during selected cycles
|
Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Time to maximum plasma concentration (Tmax) of PF-07104091 after a single dose and multiple dose
Time Frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Time to peak concentration of PF-07104091 during selected cycles
|
Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast) of PF-07104091
Time Frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
AUC of PF-07104091 will be calculated at selected cycles
|
Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Area under the curve of PF-07104091 with or without food
Time Frame: From baseline through time to event on study or study completion (approximately 2 years)
|
AUC of PF-07104091 in plasma and whether absorption of the drug is affected when taken by food
|
From baseline through time to event on study or study completion (approximately 2 years)
|
Maximum plasma concentration of PF-07104091 with or without food
Time Frame: From baseline through time to event on study or study completion (approximately 2 years)
|
Peak concentrations of PF-07104091 in plasma and whether absorption of the drug is affected when taken by food
|
From baseline through time to event on study or study completion (approximately 2 years)
|
To document any preliminary evidence of antitumor activity of PF-07104091 by time to event endpoints
Time Frame: From baseline through time to event on study or study completion (approximately 2 years)
|
Time from first assessment of event endpoint to last assessment of using RECIST 1.1
|
From baseline through time to event on study or study completion (approximately 2 years)
|
To document any preliminary evidence of antitumor activity of PF-07104091 as a single agent and in combination with palbociclib and in combination with letrozole or fulvestrant or fulvestrant alone by objective response rate (ORR) in dose escalation
Time Frame: From baseline and every 8 weeks through disease progression or study completion (approximately 2 years)
|
Percentage of participants with a best overall response of CR or PR using RECIST 1.1
|
From baseline and every 8 weeks through disease progression or study completion (approximately 2 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 16, 2020
Primary Completion (Anticipated)
January 7, 2025
Study Completion (Anticipated)
January 7, 2026
Study Registration Dates
First Submitted
August 21, 2020
First Submitted That Met QC Criteria
September 11, 2020
First Posted (Actual)
September 17, 2020
Study Record Updates
Last Update Posted (Estimate)
March 10, 2023
Last Update Submitted That Met QC Criteria
March 8, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Letrozole
- Fulvestrant
- Palbociclib
Other Study ID Numbers
- C4161001
- 2022-001679-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on PF-07104091 monotherapy dose escalation
-
PfizerRecruitingBreast Cancer | Solid TumorsChina, United States, Bulgaria, Spain, Brazil, Czechia, Argentina, South Africa, Mexico
-
PfizerCompleted
-
PfizerTerminatedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Olatec Therapeutics LLCRecruitingArthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout AttackUnited States, Spain, France
-
PfizerCompletedNon-Alcoholic Fatty Liver Disease (NAFLD)United States
-
University of California, San FranciscoNot yet recruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
PfizerCompleted
-
Weill Medical College of Cornell UniversityActive, not recruiting
-
Cliniques universitaires Saint-Luc- Université...UnknownHead and Neck CancerBelgium
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting